Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and …
Objective To evaluate pathological complete response as a surrogate endpoint for disease-
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …
[HTML][HTML] Antibody therapeutics and immunoregulation in cancer and autoimmune disease
M Yasunaga - Seminars in cancer biology, 2020 - Elsevier
Cancer and autoimmune disease are closely related, and many therapeutic antibodies are
widely used in clinics for the treatment of both diseases. Among them, the anti-CD20 …
widely used in clinics for the treatment of both diseases. Among them, the anti-CD20 …
Evidence-based public policy making for medicines across countries: findings and implications for the future
Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing
prevalence of non-communicable diseases (NCDs) and new premium priced medicines for …
prevalence of non-communicable diseases (NCDs) and new premium priced medicines for …
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal
growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced …
growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced …
Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries?
Y Kim, HY Kwon, B Godman, E Moorkens… - Frontiers in …, 2020 - frontiersin.org
Objective To compare the market dynamics of biosimilar infliximab among four Organization
for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and …
for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and …
[PDF][PDF] Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and …
Background Achieving a pathological complete response (pCR) is believed to correlate with
oncological outcomes in human epidermal growth factor receptor-2-positive (HER2+) breast …
oncological outcomes in human epidermal growth factor receptor-2-positive (HER2+) breast …
[HTML][HTML] Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis
Background The recommended preoperative approach for HER2-positive breast cancer is
unclear. We aimed to investigate the following: i) what is the optimal neoadjuvant regimen …
unclear. We aimed to investigate the following: i) what is the optimal neoadjuvant regimen …
Use of biosimilar medications in oncology
PURPOSE: The increased number and expanded utilization of biosimilars raise important
considerations for their safe and appropriate use in oncology practice. This report provides …
considerations for their safe and appropriate use in oncology practice. This report provides …
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a …
MD Pegram, I Bondarenko, MMC Zorzetto… - British Journal of …, 2019 - nature.com
Background This randomised, double-blind study compared PF-05280014 (a trastuzumab
biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union …
biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union …
[HTML][HTML] Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal …
X Pivot, M Pegram, J Cortes, D Lüftner… - European Journal of …, 2019 - Elsevier
Background We assessed long-term cardiac safety and efficacy in patients with human
epidermal growth factor receptor 2–positive early breast cancer treated with a trastuzumab …
epidermal growth factor receptor 2–positive early breast cancer treated with a trastuzumab …